尤瑞克林治疗急性脑梗死临床疗效观察

目的探讨尤瑞克林治疗急性脑梗死的临床疗效。方法将62例急性脑梗死患者随机分为对照组和尤瑞克林治疗组,两组均给予抗血小板聚集、控制血压等常规治疗,治疗组加用尤瑞克林治疗,共静脉滴注14d,观察两组患者治疗前及治疗后14d神经功能缺损程度、临床疗效及生化指标变化。结果治疗组患者神经功能恢复明显优于对照组,两组治疗后神经功能评分比较,差异有统计学意义(P=0.025),两组临床疗效差异有统计学意义(P=0.021),治疗组治疗前后实验室指标无明显变化(P0.05)。结论尤瑞克林能有效治疗急性脑梗死。

Application of Urinary Kallikrein in Patients with Acute Cerebral Infarction MAO

Objective To investigate the efficacy of Urinary Kallikrein in patients with acute cerebral infarction （ACI）. Methods Sixty-two ACI patients were randomly divided into the control group and the Urinary Kallikrein group. Both groups of patients were received conventional therapy, such as anti-platelet aggregation and control of blood pressure. Besides the conventional therapy, The patients in the Urinary Kallikrein group also received Urinary Kallikrein treatment for 14 days. The patients were evaluated by the neurologic function score, therapeutic efficiency and biochemical indicator before and after 14 days therapy. Results The neurologic functional recovery of the Urinary Kallikrein group obviously surpassed than that of the control group. There was significantly different between the two groups after 14 days therapy in the neurologic function score and the total efficiency （P=0.025 and P=-0.021 respectively）. In the Urinary Kallikrein group, there was not significantly different between before and after 14 days therapy in biochemical indicator （P〉0.05）. Conclusion Urinary Kallikrein treatment on acute cerebral infarction was effective.